Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 12,00€(+173,97%). Der Median liegt bei 10,96€(+150,23%).
Kaufen | 14 |
Halten | 17 |
Verkaufen | 4 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”). With the closing of the transaction, bluebird's common stock has ceased trading and will no longer be publicly listed. Carlyle and SK Capital have provided significant primary capital to support and scale bluebir.» Mehr auf businesswire.com
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer
WASHINGTON & NEW YORK--(BUSINESS WIRE)--Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) today announced that the tender offer commenced on March 7, 2025 to acquire all of the outstanding common stock of bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) for either (x) $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right (“CVR”) if bluebird's c.» Mehr auf businesswire.com
bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today reminds all stockholders to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of bluebird common stock by 11:59 p.m. Eastern on May 29, 2025. Stockholders that hold shares of bluebird through a broker or other nominee may be subject to a processing cutoff that is prior to the tender deadline, so it is important to act now. Additi.» Mehr auf businesswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 35,78 Mio | 107,93% |
Bruttoeinkommen | 24,47 Mio | 462,25% |
Nettoeinkommen | −26,87 Mio | 58,46% |
EBITDA | −22,75 Mio | 50,39% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 42,68 Mio€ |
Anzahl Aktien | 9,79 Mio |
52 Wochen-Hoch/Tief | 25,08€ - 2,81€ |
Dividenden | Nein |
Beta | 0,37 |
KGV (PE Ratio) | −0,24 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | −0,84 |
KUV (PS Ratio) | 0,47 |
Unternehmensprofil
Name | Bluebird Bio Aktie |
CEO | Andrew Obenshain |
Mitarbeiter | 248 |
Assets entdecken
Shareholder von Bluebird Bio Aktie investieren auch in folgende Assets